The ultimate companion for D2's Trials of Osiris. Look up everything on your opponents or yourself and see your game improve!
The ultimate companion for D2's Trials of Osiris. Look up everything on your opponents or yourself and see your game improve!
Destiny Trials Report is the ultimate companion for players of Trials of Osiris, a game mode in Bungie's video game Destiny 2. While loading your next match yo…
2024-02-18Destiny 2 Raid Report: Elevating Your Game 2024-02-11Guide to Choosing the Best Class in Destiny 2 2024-02-11Navigating Destiny 2 with the D2 Armor Picker 2024-02-06Destiny 2: Crota's End The Ultimate Guide 2024-02-01The Evolution and Future of Destiny 2 DLC ...
Hello! We're the people creating Trials Report, Guardian Report, Crucible Report and PUBG Report. If you like us you can support us with coffee.If you support us you will receive our eternal thanks an
DESTINY-Lung02是一项全球随机II期试验,旨在评估德曲妥珠单抗治疗HER2m不可切除和/或转移性非小细胞肺癌患者的安全性和疗效,这些患者在接受至少一种抗癌治疗方案(必须包含铂类化疗)期间或之后发生疾病复发或进展。患者按2:1随机接受德曲妥珠单抗5.4mg/kg(n=102)或6.4mg/kg(n=50)。
DESTINY-Lung05 II期临床研究的分析结果显示,优赫得®5.4mg/kg剂量方案的客观缓解率为58.3%;经研究者评估的PFS为10.8 个月。可控的安全性证实了5.4mg/kg是治疗既往...
基于DESTINY-Breast04试验的结果,德曲妥珠单抗(5.4mg/kg)在40多个国家被批准用于治疗不可切除或转移性HER2-low(IHC 1+或IHC 2+/ISH阴性)乳腺癌的成人患者,这些患者在转移阶段中接受过一次全身治疗或在完成辅助化疗期间或六个月内疾病复发。 基于DESTINY-Lung01和DESTINY-Lung02研究的突破性成果,德曲妥珠单抗(5.4 ...
DESTINY-Lung05 II期临床研究的分析结果显示,优赫得®5.4mg/kg剂量方案的客观缓解率为58.3%;经研究者评估的PFS为10.8个月。可控的安全性证实了5.4mg/kg是治疗既往接受过治疗的HER2突变晚期肺癌患者的最佳剂量。 …
We report here the first prospective evaluation of the prognostic impact of TF in 2 independent precision medicine studies enrolling pts referred to consider their eligibility to early phase trials. Methods: All consecutive adult pts wi...